NANO — Nanobiotix SA Share News
0.000.00%
Last trade - 00:00- €971.36m
- €967.08m
- €7.84m
Brief: Nanobiotix Announces Achievement Of $20M Development Milestone Payment
Brief: Nanobiotix Announces Achievement Of $20M Development Milestone Payment Related To Ongoing Global Phase 3 Head And Neck Cancer Study
Europe Research Roundup: Berkeley Group, Sodexo, Whitbread
Brief: Johnson & Johnson Reports 10.2% Passive Stake In Nanobiotix SA As Of Nov 9 - SEC Filing
Brief: Nanobiotix Announces Closing Of Global Offering
Brief: Nanobiotix Announces Pricing Of Capital Increase
Brief: Nanobiotix Announces Launch Of Global Follow-On Offering
Brief: Nanobiotix: Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3
Brief: Nanobiotix Announces Oral Presentation Of Final Results From Early-Stage Dose Expansion Study Of Head And Neck Cancer Treatment
Brief: Nanobiotix Presents First Data From Study On NBTXR3 For Patients With Locally Advanced Pancreatic Cancer
Brief: Nanobiotix Provides Financial Results For First Half Of 2023
Brief: Nanobiotix SA Says H1 Net Loss Attributable To Common Shareholders Was EUR 28.1 Million, Or EUR 0.80 Per Share
Refinitiv Newscasts - UK Week Ahead: European stocks edge higher on ECB rate pause expectations
Refinitiv Newscasts - Reuters Today: Lower inflation seems to be making UK consumers less gloomy
Jefferies resumes Nanobiotix at 'buy' as JNJ deal provides 'big pharma muscle'
Europe Research Roundup: Aston Martin, AT & S, Nanobiotix SA
Brief: Nanobiotix Announces First Patient Injected In New Phase 1/2 Study Evaluating Radiotherapy-Activated Nbtxr3 Plus Anti-Pd-1 For Patients With Advanced Cancers
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
Nanobiotix gains on agreement with J&J unit for cancer drug